Since Meduna in 1934 introduced the treatment of schizophrenic states by induced epileptiform convulsions, a volume of literature has appeared on the use of cardiazol as convulsant. But although cardiazol proved immensely superior to the original camphor, it is not without some serious disadvantages. These led naturally to the search for further improvement in the convulsant agent, and it is with one of the successors to cardiazol, introduced by Walk and Mayer-Gross (1938), and known as azoman or triazol 156, that this record is concerned.